CHD5: A Potential Drug Target for Cancer (G26038)

Target Name: CHD5

NCBI ID: G26038

CHD5

CHD5: A Potential Drug Target for Cancer

CHD5, also known as CHD5-HUMAN, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. CHD5 is a gene that encodes a protein known as CD11b, which is a type of adhesion molecule that is expressed in various tissues throughout the body.

CD11b is known for its role in the development and progression of various diseases, including cancer. Studies have shown that high levels of CD11b expression are associated with poor prognosis in cancer patients. Additionally, CD11b has been shown to play a role in the regulation of cell proliferation and the development of cancer stem cells.

As a drug target, CHD5 is being investigated for its potential to treat various diseases, including cancer. One approach to targeting CHD5 is to use small molecules or antibodies that can bind to the CD11b protein and prevent it from interacting with its cell surface receptors. This approach is being used to develop new treatments for cancer, including inhibitors of CD11b-mediated signaling pathways.

Another approach to targeting CHD5 is to use it as a biomarker to predict the prognosis of cancer patients. Studies have shown that CHD5 expression is associated with poor prognosis in cancer patients, and that higher levels of CHD5 expression are associated with shorter survival times. This makes CHD5 a potential biomarker for cancer, and researchers are working to develop new methods for its diagnosis and monitoring.

In addition to its potential as a drug target and biomarker, CHD5 is also being studied for its potential role in cancer progression. Studies have shown that CD11b is involved in the regulation of cell migration and the development of cancer stem cells. This suggests that CD11b may play a role in the progression of cancer from its initial stages to more advanced stages.

Overall, CHD5 is a gene that is being studied for its potential as a drug target and biomarker for the treatment of cancer. While more research is needed to fully understand its role, its potential as a new treatment option for cancer is an exciting area of study that is gaining attention from researchers around the world.

Protein Name: Chromodomain Helicase DNA Binding Protein 5

Functions: Chromatin-remodeling protein that binds DNA through histones and regulates gene transcription. May specifically recognize and bind trimethylated 'Lys-27' (H3K27me3) and non-methylated 'Lys-4' of histone H3. Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin. Plays a role in the development of the nervous system by activating the expression of genes promoting neuron terminal differentiation. In parallel, it may also positively regulate the trimethylation of histone H3 at 'Lys-27' thereby specifically repressing genes that promote the differentiation into non-neuronal cell lineages. Regulates the expression of genes involved in cell proliferation and differentiation. Downstream activated genes may include CDKN2A that positively regulates the p53/TP53 pathway, which in turn, prevents cell proliferation. In spermatogenesis, it probably regulates histone hyperacetylation and the replacement of histones by transition proteins in chromatin, a crucial step in the condensation of spermatid chromatin and the production of functional spermatozoa

The "CHD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets